Next Article in Journal
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide
Previous Article in Journal
Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside

1
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy
2
Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
3
Intensive Care Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(6), 857; https://doi.org/10.3390/cancers11060857
Submission received: 14 May 2019 / Revised: 10 June 2019 / Accepted: 12 June 2019 / Published: 20 June 2019

Abstract

Mucositis is one of the most common debilitating side effects related to chemotherapy (CT), radiation therapy (RT), targeted agents and immunotherapy. It is a complex process potentially involving any portion of the gastrointestinal tract and injuring the mucosa, leading to inflammatory or ulcerative lesions. Mechanisms and clinical presentation can differ according both to the anatomic site involved (oral or gastrointestinal) and the treatment received. Understanding the pathophysiology and management of mucosal injury as a secondary effect of anti-cancer treatment is an important area of clinical research. Prophylaxis, early diagnosis, and adequate management of complications are essential to increase therapeutic success and, thus, improve the survival outcomes of cancer patients. This review focuses on the pathobiology and management guidelines for mucositis, a secondary effect of old and new anti-cancer treatments, highlighting recent advances in prevention and discussing future research options.
Keywords: mucosal injury; mucositis; mucosal impairment; anti-cancer treatments mucosal injury; mucositis; mucosal impairment; anti-cancer treatments

Share and Cite

MDPI and ACS Style

Basile, D.; Di Nardo, P.; Corvaja, C.; Garattini, S.K.; Pelizzari, G.; Lisanti, C.; Bortot, L.; Da Ros, L.; Bartoletti, M.; Borghi, M.; et al. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers 2019, 11, 857. https://doi.org/10.3390/cancers11060857

AMA Style

Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, et al. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers. 2019; 11(6):857. https://doi.org/10.3390/cancers11060857

Chicago/Turabian Style

Basile, Debora, Paola Di Nardo, Carla Corvaja, Silvio Ken Garattini, Giacomo Pelizzari, Camilla Lisanti, Lucia Bortot, Lucia Da Ros, Michele Bartoletti, Matteo Borghi, and et al. 2019. "Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside" Cancers 11, no. 6: 857. https://doi.org/10.3390/cancers11060857

APA Style

Basile, D., Di Nardo, P., Corvaja, C., Garattini, S. K., Pelizzari, G., Lisanti, C., Bortot, L., Da Ros, L., Bartoletti, M., Borghi, M., Gerratana, L., Lombardi, D., & Puglisi, F. (2019). Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers, 11(6), 857. https://doi.org/10.3390/cancers11060857

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop